|Positive WB detected in||Jurkat cells, K-562 cells, HSC-T6 cells, NIH/3T3 cells|
|Western Blot (WB)||WB : 1:5000-1:10000|
|Sample-dependent, check data in validation data gallery|
67355-1-Ig targets P27; KIP1 in WB applications and shows reactivity with Human, mouse, rat samples.
|Tested Reactivity||Human, mouse, rat|
|Host / Isotype||Mouse / IgG1|
|Immunogen||P27; KIP1 fusion protein Ag14634|
|Full Name||cyclin-dependent kinase inhibitor 1B (p27, Kip1)|
|Calculated molecular weight||198 aa, 22 kDa|
|Observed molecular weight||27 kDa|
|GenBank accession number||BC001971|
|Gene ID (NCBI)||1027|
|Purification Method||Protein G purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Aliquoting is unnecessary for -20oC storage.|
DKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.